Abbott (ABT) Stock Shrugs Off Q3 Results As Spin Off Looms

Abbott Laboratories came into this Q3 2026 report with a rich valuation and a reputation as a dependable healthcare compounder, yet the stock had slipped over the last month. Today, the shares are only up about 0.8% despite comparable sales growth of roughly 7% and adjusted earnings per share of US$1.42 that matched the script management had been setting. That muted price reaction sits awkwardly against a business posting higher gross and operating margins, and unveiling a plan to spin off...